News | October 16, 2025
Syngene International invests in peptide laboratory in Bengaluru
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
Lutavit A/D3 1000/200 NXT provides a combination of vitamin A and vitamin D3 in one formulation
The anatomage table is one of the most advanced 3D real-tissue–based anatomy visualization systems in the world
The Cranbury facility represents a strategic advancement of the company's operations in the Unted States
Updated indication expands treatment options for patients with ulcerative colitis and Crohn’s disease when tumor necrosis factor (TNF) blockers are clinically inadvisable
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers
New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Subscribe To Our Newsletter & Stay Updated
